The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma Article

Industry Collaboration International Collaboration

cited authors

  • Colombo, Nicoletta; Oza, Amit M.; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Weberpals, Johanne, I; Clamp, Andrew R.; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W.; Gancedo, Margarita Amenedo; Fong, Peter C.; Goh, Jeffrey C.; O'Malley, David M.; Armstrong, Deborah K.; Banerjee, Susana; Garcia-Donas, Jesus; Swisher, Elizabeth M.; Meunier, Juliette; Cameron, Terri; Maloney, Lara; Goble, Sandra; Bedel, Josh; Ledermann, Jonathan A.; Coleman, Robert L.

authors

Publication Date

  • October 1, 2020

webpage

published in

category

keywords

  • Elderly patients
  • Maintenance
  • Ovarian cancer
  • PARP inhibitor
  • Rucaparib

start page

  • 101

end page

  • 111

volume

  • 159

issue

  • 1